Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Real-World Study of Anti-SARS-CoV-2 Monoclonal Antibodies in Patients at High Risk of Severe Forms of Covid-19

NCT05439044 is registered in ClinicalTrials.gov with Assistance Publique - Hôpitaux de Paris as lead sponsor.

NCT NCT05439044
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05439044 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Real-World Study of Anti-SARS-CoV-2 Monoclonal Antibodies in Patients at High Risk of Severe Forms of Covid-19
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Observational
Overall status
Completed
Start date
August 1, 2021
Completion date
December 31, 2022
Enrollment
4,235 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

immunocompromised patients